Drug Resistance Among Asymptomatic Infection

NCT ID: NCT03648411

Last Updated: 2020-07-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

765 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-12

Study Completion Date

2020-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A cross-sectional study will be conducted in selected 2 sentinel sites for assessment of drug resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although malaria prevalence is decreasing in Myanmar, drug resistance threatens the malaria elimination by 2030 especially high risk persons including migrant population. Previous study indicated that asymptomatic malaria parasite carried drug resistance gene such as K13 mutant that is genetically responsible for artemisinin resistant falciparum malaria. These asymptomatic carries may be a source to spread the disease and it is very important to conduct the surveillance on drug resistance status among high vulnerable persons. Unfortunately, there is no study to assess the drug resistance molecular markers in asymptomatic malaria among migrant workers in Myanmar. Therefore, this study fulfills the gaps of knowledge on important of asymptomatic hidden infection exploring to formulate the recommendation for elimination of malaria in Myanmar.

In this study, asymptomatic infections are screened by rapid diagnostic test, microscopy and molecular methods.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Resistant Malaria Asymptomatic Infections Migrant Workers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Shwegyin

Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.

Drug resistance molecular markers

Intervention Type GENETIC

Proportion of the drug resistance molecular markers will be found-out and compared.

Pinlebu

Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.

Drug resistance molecular markers

Intervention Type GENETIC

Proportion of the drug resistance molecular markers will be found-out and compared.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drug resistance molecular markers

Proportion of the drug resistance molecular markers will be found-out and compared.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age above 6 year
* Migrant population (moving from their normal residence place and working at a new place such as forest related activities, gold-mines or plantation sites for more than 3 months- 3 years)
* Both sex
* Participant who give informed-consent to participate the study

Exclusion Criteria

* Known clinical malaria cases regardless of the species detected
* Patients with clinical symptoms of malaria at the time of examination
* Known history of malaria within 14 days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Malaria Control Program, Myanmar

OTHER_GOV

Sponsor Role collaborator

Department of Medical Research, Lower Myanmar

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Myat Htut Nyunt

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Myat H Nyunt, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Medical Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr. Myat Phone Kyaw

Yangon, , Burma

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Burma

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DMR_2018-108

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Artemisinin Resistance in Cambodia
NCT00479206 COMPLETED NA
Innovation Platform
NCT04558528 COMPLETED